Categories
Prostate Cancer

Taboo health topics: Prostate and testicular cancer [Video]

Prostate cancer and testicular cancer are often taboo health topics.Men remain hesitant to take action when it comes to their physical health or emotional well-being.Often, they will ignore a health issue until an emergency arises.Life Healthcare Chief Medical Officer, Dr Louis Kathan, elaborates.Tune into Newzroom Afrika channel 405 for more.

Categories
Prostate Cancer

Latest advances in tumour genetics research for prostate cancer [Video]

Omar Mian, MD, PhD, Cleveland Clinic, Cleveland, OH, discusses latest research into tumour genetics for the development of predictive and prognostic biomarkers for prostate cancer. Dr Mian describes the various techniques that have been used to discover a range of genetic variants. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Categories
Prostate Cancer

Prostate cancer and the colour of your skin [Video]

Launched: September 12, 2022Black men have a higher risk of developing prostate cancer. In this webinar, Dr Danny Vesprini discusses some of the research in this area and factors that can influence this risk.Dr Danny Vesprini is a radiation oncologist who treats prostate and breast cancer at the Sunnybrook Odette Cancer Centre in Toronto. He is an affiliate scientist in the biological sciences at the Sunnybrook Research Institute and an assistant professor in the department of radiation oncology at the University of Toronto. Dr Vesprini’s research includes a focus on the genetic predisposition to aggressive prostate cancer. He is one of the principal investigators of the Sunnybrook Active Surveillance Program, and director of the Male Oncology Research and Education (MORE) program, which focuses on men at increased risk of developing prostate cancer.

Categories
Prostate Cancer

Prostate Cancer | Smartlife [Video]

Prostate cancer is the leading cause of cancer death among men of all races. However, prostate cancer is very treatable and has a very high survival rate, says Dr. Daniel Martinez, a urologist with Baptist Health South Florida, and he highlights the new era of treatments available for this disease. Dr. Martinez, also an expert on sex medicine, debunks men’s fear of impotence and erectile dysfunction and pinpoints the underlying reasons men ignore the signs and delay screening for prostate problems. He also touches upon the revised screening guidelines.Have a health question? Our medical advisors are standing by visit www.allhealthtv.com/ask-hanna. -AllHealthGo is South Florida PBS’ exciting new digital health media venture that is building a trusted source of health and wellness information for consumers hungry for information and understanding. Through AllHealthGo’s Health Channel, the only 24/7 health and wellness TV channel in the country, we connect you with medical and well-being specialists in real-time, promoting healthier lifestyle options. In partnership with prestigious organizations, the service aims to empower you with the most up-to-date information, enabling you to take more control of your and your family’s health. To complement the live interactions with medical and well-being specialists, the AllHealthGo offers a robust companion digital platform that provides access to specialized services.#prostatecancer #prostatecancerawareness

Categories
Prostate Cancer

Improving Survival for Men with Prostate Cancer by Improving Clinical Trials and Meta Analyses [Video]

Date of Lecture: 3 November 2022About the Lecture:Randomised clinical trials are the cornerstone of evidence-based medicine. Professor Parmar will present how the design of the randomised clinical trial has been changed to improve outcomes for patients more quickly. This will be exemplified throughout by the STAMPEDE trial. The trial was started in 2005 when men with metastatic prostate cancer had an expected survival of approximately 3 years and no new effective treatments had been identified for over 40 years. Over the subsequent 17 years, through the STAMPEDE trial (together with other contemporaneous trials) the expected survival period has grown to 7 years, testing and introducing 4 new treatments for men with this disease. Professor Parmar will show how this model is being applied worldwide to many diseases including neurodegenerative diseases such as motor neuron disease, progressive multiple sclerosis, Parkinsons disease and dementia where the outcomes for patients are poor and little or no progress has been made for decades.About the Speaker:Max Parmar is a Professor of Medical Statistics and Epidemiology and Director of both the MRC Clinical Trials Unit at UCL and the Institute of Clinical Trials and Methodology at University College London.